Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Anlotinib Hydrochloride: Multi-Target TKI Workflows for T...

    2026-03-06

    Anlotinib Hydrochloride: Multi-Target TKI Workflows for Tumor Angiogenesis Inhibition

    Principle and Setup: Targeting the Angiogenic Axis in Cancer Research

    Anlotinib (hydrochloride) is a next-generation anti-angiogenic small molecule, designed as a multi-target tyrosine kinase inhibitor (TKI) with nanomolar potency against key pro-angiogenic drivers: VEGFR2 (IC₅₀: 5.6 ± 1.2 nM), PDGFRβ (IC₅₀: 8.7 ± 3.4 nM), and FGFR1 (IC₅₀: 11.7 ± 4.1 nM). By simultaneously blocking these kinases and downstream ERK signaling, anlotinib achieves superior endothelial cell migration inhibition and capillary tube formation suppression compared to sunitinib, sorafenib, and nintedanib. This multi-modal approach is pivotal for dissecting tumor angiogenesis mechanisms and evaluating new anti-cancer strategies.

    APExBIO supplies research-grade anlotinib hydrochloride (SKU C8688) with validated purity and batch consistency, ensuring reliable performance in cellular and in vivo models. Its pharmacokinetic profile—marked by high bioavailability (up to 77% in dogs), robust tissue penetration (notably in lung, liver, kidney, heart, and tumor), and favorable safety margins (median LD₅₀: 1735.9 mg/kg)—makes it an ideal tool for translational and mechanistic oncology research.

    Step-by-Step: Optimizing Capillary Tube Formation and Endothelial Migration Assays

    1. Preparation and Storage

    • Aliquot anlotinib hydrochloride under sterile conditions and store at -20°C. Thaw working aliquots immediately before use to prevent degradation.
    • Prepare stock solutions in DMSO (10 mM recommended); dilute into assay medium to achieve final concentrations spanning 1–100 nM, ensuring DMSO content does not exceed 0.1% v/v in cultures.

    2. Capillary Tube Formation Assay (EA.hy 926 or HUVEC Models)

    1. Coat 96-well plates with Matrigel (50 μL/well), solidify at 37°C for 30 min.
    2. Seed endothelial cells (1–2 × 104 cells/well) in EGM-2 medium supplemented with VEGF, PDGF-BB, or FGF-2 to induce tube formation.
    3. Add graded concentrations of anlotinib hydrochloride. Negative control: vehicle only; positive control: known angiogenesis inhibitor.
    4. Incubate for 4–8 hours. Image wells using phase-contrast microscopy.
    5. Quantify tube length, number of junctions, and loops using ImageJ or comparable software.

    Expected result: Anlotinib demonstrates concentration-dependent inhibition of tube formation, with near-complete suppression at ≥30 nM, outperforming sunitinib and sorafenib under matched conditions [see detailed protocol].

    3. Endothelial Cell Migration (Scratch or Transwell Assay)

    1. For scratch assays, create a uniform wound in confluent endothelial monolayers using a pipette tip.
    2. Treat with anlotinib at indicated concentrations; monitor wound closure over 12–24 hours.
    3. For transwell assays, seed cells in upper chambers; chemoattractant in the lower chamber; treat with anlotinib.
    4. Stain and count migrated cells after 6–12 hours.

    Anlotinib hydrochloride yields robust inhibition of migration, with IC₅₀ values aligning with its anti-VEGFR2 potency. This dual readout (migration and tube formation) provides orthogonal validation of anti-angiogenic efficacy.

    4. Downstream Signaling Analysis

    • Harvest cell lysates post-treatment; immunoblot for p-ERK, total ERK, p-Akt, p-VEGFR2, and housekeeping controls.
    • Normalize phospho-signal to total protein; expect dose-dependent suppression of ERK phosphorylation, confirming pathway blockade.

    Advanced Applications and Comparative Advantages

    1. Translational Oncology and Tumor Models

    Anlotinib's ability to cross the blood-brain barrier and accumulate in tumor tissue (demonstrated by high tissue/plasma ratios) supports its use in advanced xenograft or orthotopic tumor models. In a landmark case report, anlotinib delivered significant tumor burden reduction in a patient with metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT) after failure of standard chemotherapies. Lymph node metastases regressed markedly after four cycles, and maintenance therapy was well-tolerated, with manageable side effects—underscoring its translational promise for rare, angiogenesis-driven malignancies.

    2. Comparative Mechanistic Insights

    Relative to sunitinib, sorafenib, and nintedanib, anlotinib hydrochloride exhibits superior multi-target inhibition, with lower IC₅₀s for VEGFR2, PDGFRβ, and FGFR1. This broad-spectrum profile enables researchers to dissect both canonical and compensatory angiogenic pathways. As detailed in "Redefining Tumor Angiogenesis Inhibition", anlotinib's integration into cell-based and in vivo models propels anti-angiogenic research beyond conventional paradigms, offering both depth (mechanistic resolution) and breadth (applicability across tumor types).

    3. Expanding the Toolkit for ERK Pathway and Tyrosine Kinase Signaling Studies

    The downstream inhibition of the ERK signaling pathway by anlotinib enables precise mapping of tyrosine kinase signaling cascades in cancer research. This is especially valuable for labs investigating resistance mechanisms, adaptive angiogenesis, or the interplay of multiple growth factor networks—areas where single-target inhibitors often fall short.

    Additional workflow guidance can be found in "Solving Real Lab Challenges with Anlotinib (hydrochloride)", which provides scenario-driven troubleshooting for cell-based angiogenesis and cytotoxicity assays, complementing the mechanistic depth of the articles above.

    Troubleshooting and Optimization Tips for Reproducible Results

    • Dosing Precision: Given anlotinib's nanomolar potency, carefully calibrate dilution schemes and validate actual concentrations in medium using LC-MS/MS if possible. Avoid repeated freeze-thaw cycles.
    • Assay Controls: Always include both positive (e.g., sunitinib) and negative (vehicle) controls in migration and tube formation assays. This contextualizes anlotinib's superior inhibitory effect.
    • Serum and Growth Factor Conditions: Standardize serum concentrations and growth factor additions; excessive VEGF/FGF-2 can mask subtle inhibitor effects. Titrate to physiologically relevant levels.
    • Cell Line Authentication: Regularly verify endothelial cell identity and passage number; drift in phenotype can alter angiogenic responsiveness and affect IC₅₀ measurements.
    • Signaling Pathway Readouts: For ERK pathway inhibition, optimize lysis timing post-treatment (typically 15–60 min) to capture transient phosphorylation events. Always normalize to total protein or housekeeping genes.
    • Batch-to-Batch Consistency: Source anlotinib hydrochloride from reputable suppliers like APExBIO to ensure quality and reproducibility across experiments.
    • Data Analysis: Use blinded quantification and automated image analysis where possible to reduce bias in capillary tube and migration assays.

    For a comprehensive troubleshooting matrix and comparison with other angiogenesis inhibitors, "Anlotinib Hydrochloride: Advanced Protocols for Tumor Angiogenesis" provides actionable tips and workflow enhancements tailored for high-throughput and translational workflows.

    Future Outlook: Integrative Platforms and Novel Applications

    The next frontier for anlotinib hydrochloride lies in multi-omics and precision oncology. High-content imaging, single-cell transcriptomics, and CRISPR-engineered models are increasingly being used to map the impact of VEGFR2/PDGFRβ/FGFR1 inhibition on tumor microenvironment dynamics and resistance emergence. Anlotinib's capacity to inhibit multiple tyrosine kinase signaling pathways positions it as a versatile probe in these advanced systems.

    Emerging studies are also exploring combinatorial regimens—pairing anlotinib with immunotherapies or metabolic inhibitors—to enhance tumor control and overcome resistance. Given its excellent safety profile in preclinical models and documented efficacy in rare, refractory tumors [clinical case reference], anlotinib is primed for integration into next-generation therapeutic and investigative platforms.

    For research teams seeking to redefine the boundaries of anti-angiogenic drug discovery, Anlotinib (hydrochloride) from APExBIO offers an unparalleled blend of mechanistic precision, workflow versatility, and translational relevance—empowering rigorous, high-impact cancer research across the bench-to-bedside continuum.